{"pageContent": "Background: Luteinizing hormone-releasing hormone (LHRH) agonists have been widely used as effective agents in endocrine therapy for prostate cancer. Continuous administration of the drug results in profound suppression of testicular androgen production. However, the side effects on erectile function have not been fully investigated.", "metaData": {"source": "Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account?\nhttps://pubmed.ncbi.nlm.nih.gov/18040996/"}}